Brief: Bioinvent Reports Interim Safety Data, Early Signs Of Efficacy In Phase 1/2A Trial

BioInvent International AB

21/06/2023 11:16

June 21 (Reuters) - BioInvent International AB
 BINV.ST :
    * BIOINVENT REPORTS STRONG INTERIM SAFETY DATA AND EARLY
SIGNS OF
EFFICACY IN PHASE 1/2A TRIAL WITH ANTI-TNFR2 ANTIBODY BI-1808 IN
ADVANCED MALIGNANCIES
    * WELL-TOLERATED INFUSIONS, NO DOSE LIMITING TOXICITIES OR
SERIOUS
ADVERSE EVENTS
    * STABLE DISEASE OBSERVED IN SIX PATIENTS SO FAR; EFFICACY
TO BE
FURTHER EXPLORED IN PHASE 2A
    * NO SIGNIFICANT SAFETY CONCERNS WERE OBSERVED IN RELATION
TO
ADMINISTRATION OF BI-1808 AS SINGLE AGENT IN PHASE 1, PART A OF
TRIAL

Source text for Eikon:  ID:nMFN61BWxP 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))